JACKSONVILLE, FL / ACCESSWIRE / May 9, 2017 / TapImmune (TPIV) is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense.
The company has 4 different Phase II studies for the development of novel vaccines to treat aggressive breast and ovarian cancers, and is planning to submit an Investigational New Drug (IND) application with the FDA for another breast cancer vaccine this year.
Additionally, TapImmune recently added Richard Kenney, MD, FACP, as Medical Director for the Company to lead the clinical development program. Dr. Kenney brings deep clinical development and FDA process experience to the Company as it continues to develop T-cell cancer vaccines that target refractive breast and ovarian tumors.
TapImmune (TPIV) is developing immunotherapies for a variety of cancers that are designed to target both tumors and metastatic disease. The company's next-generation technology is designed to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company's off-the-shelf vaccines boost patients' immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells.
In short, TapImmune (TPIV) is developing cutting-edge vaccines that attack ovarian and breast cancer with a vengeance.
Investors can read more about TapImmune in the article: TapImmune (TPIV): U.S. Department of Defense Fully Funds Phase II Breast Cancer Study
About MicrocapResearch.com
Launched in 2014, MicrocapResearch.com is an investment research service featuring small and microcap stocks that have key drivers the publishers believe will drive share prices higher in the near term. Our microcap picks averaged a fully documented 100.6% gain during 2015 measured from the date prior to our reports, to the post report high, and a 137% gain in 2016 during the same period of measurement. The publishers of MicrocapResearch.com are not registered as investment advisors in any jurisdiction. Investing in stocks, particularly small and microcap stocks, is highly speculative. Never invest in any stock unless you can afford to lose your entire investment and consult your investment professional before making any investment decision. Please see applicable disclosures and site-wide disclaimer at MicrocapResearch.com.
CONTACT:
Inquiries@MicrocapResearch.com
SOURCE: MicrocapResearch.com
ReleaseID: 462524
